Repotrectinib potently and selectively inhibits the abnormally activated kinase signaling pathways of ROS1 and NTRK, effectively overcomes resistance mutations to conventional targeted therapies, and exhibits favorable central nervous system penetration.
Authentic
Guarantee
Fast Delivery
Privacy Repotrectinib, a targeted drug for ROS1-positive non-small cell lung cancer, provides relief, but its potential side effects require timely detection ···【Read More】
Update: 10 Mar,2026Source: Haiou HealthViews: 72
Repotrectinib has demonstrated breakthrough therapeutic efficacy against specific gene-mutant lung cancers, providing an important treatment option fo···【Read More】
Update: 10 Mar,2026Source: Haiou HealthViews: 72
Repotrectinib, a novel kinase inhibitor, offers a new treatment option for certain lung cancer patients. Understanding its indications, contraindicati···【Read More】
Update: 10 Mar,2026Source: Haiou HealthViews: 71
On November 16, 2023, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved ripretinib (Augtyro) for the treatm···【Read More】
Update: 03 Mar,2026Source: Haiou HealthViews: 72
Ripretinib (Augtyro) is a next-generation targeted anticancer drug developed by Bristol-Myers Squibb (BMS), offering a new precision treatment option ···【Read More】
Update: 03 Mar,2026Source: Haiou HealthViews: 72
Repotrectinib is a novel, oral, small-molecule, multi-target tyrosine kinase inhibitor (TKI) primarily used to treat advanced solid tumors harboring s···【Read More】
Update: 03 Mar,2026Source: Haiou HealthViews: 72
Repotrectinib, an innovative ROS1 and NTRK-targeting inhibitor, can simultaneously inhibit multiple oncogenic targets, exhibiting broad-spectrum anti-···【Read More】
Update: 03 Mar,2026Source: Haiou HealthViews: 73
Repotrectinib is a new generation of targeted anticancer drug developed by Bristol-Myers Squibb (BMS), providing a new option for precision treatment ···【Read More】
Update: 03 Mar,2026Source: Haiou HealthViews: 72
Copyright2024@ BIGBEAR All right reserved BIGBEAR



